GLP-1 Genetic Testing: Should You Get Tested Before Starting Treatment?
Stanford researchers just discovered that 1 in 10 people are genetically resistant to GLP-1 drugs. Should you pay for testing before committing to months of treatment? Here's the math.
Why This Article Exists
The Stanford study published in April 2026 dropped a bomb on GLP-1 prescribing: approximately 10% of the population carries genetic variants that make these drugs meaningfully less effective. This raises a question that patients are just starting to Google: should I get tested before starting treatment?
We analyzed the science, the available testing options, and the math to give you a clear answer.
The Quick Version: What the Stanford Study Found
| Finding | Detail |
|---|---|
| Gene involved | PAM (peptidylglycine alpha-amidating monooxygenase) |
| Variant studied | p.S539W |
| Population prevalence | ~10% |
| Effect on GLP-1 levels | Higher than normal (paradoxically) |
| Effect on GLP-1 drug response | Reduced — gastric emptying not slowed, pancreatic response blunted |
| GLP-1 receptor function | Normal — the problem is upstream |
The Economics of Testing vs. Not Testing
GLP-1 medications cost $99–1,349 per month depending on the formulation and provider. Most patients don't know if they'll respond well until they've been on the medication for 2–3 months. For the ~10% who carry PAM variants, that's potentially $300–$4,000 spent on a medication that was never going to work optimally for them.
Current Testing Landscape
| Option | Coverage | Cost | Includes PAM? |
|---|---|---|---|
| Clinical pharmacogenomic panels (e.g., GeneSight, OneOme) | Many drug-response genes | $200–500 (often insurance-covered) | Not yet standard |
| Direct-to-consumer genetic tests (23andMe, Ancestry) | Broad genotyping | $100–200 | Not typically |
| Whole exome/genome sequencing | Comprehensive | $500–2,000 | Yes (if variant is looked for) |
| Targeted PAM variant testing | Specific to this variant | Not yet commercially available | By definition |
Here's the catch: dedicated PAM variant testing for GLP-1 response isn't yet a standard commercial product. The Stanford discovery is weeks old. It will take 6–12 months for diagnostic companies to develop, validate, and market specific tests. In the meantime, patients with access to existing pharmacogenomic panels or whole-genome data may be able to check for PAM variants, but it requires asking your provider specifically.
Who Should Seriously Consider Testing
You've been on a GLP-1 for 3+ months with disappointing results (minimal appetite suppression, less than 5% weight loss). You have a family history of poor GLP-1 response. You're paying out-of-pocket and want to optimize your investment before committing to long-term treatment. Or you simply want data-driven confidence before starting a medication you may take for years.
What to Do If You're Already on a GLP-1 and It's Working
Nothing. If your GLP-1 medication is producing the expected appetite suppression, weight loss, and metabolic improvements, you almost certainly don't carry a clinically significant PAM variant. Testing in this case would cost money to confirm what your body is already telling you.
What to Tell Your Doctor
Most physicians aren't yet aware of the Stanford PAM findings (the study is from April 2026). If you want to discuss testing, bring a summary of the study to your appointment. The key reference: Stanford Medicine, "One in 10 people may have resistance to GLP-1 diabetes drugs," April 10, 2026. Your doctor can determine whether pharmacogenomic testing is appropriate for your specific situation and insurance coverage.
Sources
- Stanford Medicine. "One in 10 people may have resistance to GLP-1 diabetes drugs." April 10, 2026. med.stanford.edu
- Gloyn AL, et al. Study on PAM gene variants and GLP-1 resistance. Stanford Medicine, 2026.
- ATTAIN-1 trial data (Foundayo). FDA approval documents, April 2026.